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Abstract The Fiirster energy transfer from tryptophan residues 
of membrane proteins to nystatin was measured in reconstituted 
yeast plasma membrane vesicles free of, or doped with, 
ergosterol. We wanted to elucidate whether the functional 
change of membrane transport proteins from H + symporters to 
facilitators, observed in ergosterol-containing plasma membrane 
vesicles on addition of nystatin IOpekarovfi and Tanner (1994) 
FEBS Lett. 350, 46-50], is reflected in altered protein-nystatin 
relations within the membrane. Both frequency-domain and time- 
domain time-resolved fluorescence spectroscopy showed that in 
the presence of ergosterol nystatin is located much closer to 
membrane proteins than in its absence. 
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I. Introduction 
Like other polyene antibiotics, nystatin is claimed to inter- 
act specifically with ergosterol in the yeast plasma membrane; 
the consequence of this interaction is pore formation or mem- 
brane fluidity changes. As a result, intracellular metabolites 
can freely leave the interior of the cell, which eventually leads 
to cell death (for review see [1,2]). 
Treatment with nystatin has been reported to bring about a 
rapid release of previously accumulated amino acids such as 
arginine and histidine [3-5] and other metabolites such as al- 
lantoate [6], urea [7], allantoin [8], oxalurate [9] and 7-amino- 
butyrate [10] from the yeast. These substances are released 
from the cells irrespective of their cellular distribution. Urea 
is located mainly in the cytoplasm, while basic amino acids, 
allantoin and allantoate are predominantly sequestered in vac- 
uoles. 
Recently we examined the effect of nystatin on the trans- 
port of arginine in an in vitro system of yeast plasma mem- 
brane vesicles which eliminates the interference of cellular 
compartmentation [11] and offers the possibility to change 
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nearly arbitrarily the membrane lipid composition. Arginine 
accumulation i the vesicles is driven by protonmotive force 
(pmf); however, even when the pmf is completely abolished by 
low concentrations of uncouplers no efflux of accumulated 
arginine occurs [11]. This finding reflects the unidirectionality 
of amino acid transport observed in whole yeast cells (for 
review see, e.g. [12]). Addition of low concentrations of nys- 
tatin (5-10 ktg/mg lipid) to the vesicles without ergosterol did 
not affect the arginine fluxes whereas in ergosterol-containing 
vesicles it caused a massive ffiux of the accumulated arginine 
while the magnitude of the protonmotive force in the system 
remained largely unaffected. These results suggest hat nysta- 
tin, in addition to its well-established binding to ergosterol, 
exhibits another effect in the yeast plasma membrane: at low 
concentrations it obviously alters the properties of the mem- 
brane carriers, converting them from H + symporters to facil- 
itators. 
These transport data pointing to nystatin affecting mem- 
brane proteins can be confirmed by physical methods, e.g. 
by measuring the F6rster energy transfer (FRET) [13] which 
makes it possible to estimate the distance between a donor (i.e. 
tryptophan i  membrane proteins) and an acceptor (nystatin). 
The average distance was estimated by measuring the lifetime 
of tryptophan residues in vesicles prepared from yeast plasma 
membranes fused either with E. coli phospholipids (approx. 
50% of phosphatidylethanolamine) without ergosterol, or in 
the same vesicles enriched with 12% (w/w) of ergosterol. 
2. Materials and methods 
2.1. Materials 
L-tx-Phosphatidylethanolamine (type IX from E. coli, approx. 50%), 
ergosterol and nystatin were obtained from Sigma. 
2.2. Yeast strains 
A transformed strain Saccharomyces cerevisiae RS 453 (CAN1) 
(ade 2-1, leu 2-3,112, his 3-11,15, ura 52) with a multicopy plasmid 
pWHY bearing the CAN1 gene coding for arginine permease [14] was 
used in the study. 
2.3. Media and growth conditions 
The yeast strain S. cerevisiae RS 453 (CAN 1) was grown on a yeast 
minimal medium containing 0.67% yeast nitrogen base without amino 
acids, 2% glucose and necessary bases and amino acids. 
2.4. Isolation of plasma membranes 
Plasma membranes were isolated from yeast grown at 29°C on a 
rotary shaker. At A57s = 0.5~).8 the cells were harvested, washed and 
broken by shaking with glass beads (diameter 0.45-0.5 mm). The 
plasma membranes were isolated essentially according to [15]. During 
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the isolation a mixture of 0.25 M 4-aminobenzamidine dihydrochlor- 
ide and 0.5 M phenylmethylsulphonyl floride was repeatedly added in 
amounts of 1/100 of the actual isolation solution volume. The isolated 
plasma membranes, uspended in 50 mM potassium phosphate, pH 
6.3, 20% glycerol and 1 mM EDTA, were rapidly frozen in liquid 
nitrogen and stored at -80°C. 
2.5. Preparation of  liposomes 
E. coli phospholipid liposomes (PL) were prepared as described by 
Opekarovfi et al. [14]. For preparation of ergosterol-containing lipo- 
somes (PE), chloroform solutions of ergosterol and E. coli phospho- 
lipid were mixed so that the final concentration (w/w) of ergosterol 
was 12%. The subsequent procedure was the same as above. 
2.6. Fusion of  liposomes with yeast plasma membranes 
The liposomes were mixed with yeast plasma membranes at a ratio 
of 20:1 (lipid/protein) in a final volume of 10(~200 ktl. The resulting 
plasma membrane vesicles (PLM, membranes fused with phospholipid 
liposomes; PEM, membranes fused with ergosterol-containing lipo- 
somes) were supplemented with 1 mM MgSO4 and rapidly frozen in 
liquid nitrogen. Before use the fused membranes were slowly thawed 
at room temperature and briefly sonicated with a probe-type sonifier 
(Cole-Palmer Instruments Co.). 
Measurements with individual preparations of liposomes and vesi- 
cles (PL, PE, PLM, PEM) were performed in 50 mM potassium 
phosphate buffer, pH 6.3, containing 2 mM MgSO4. Nystatin (stock 
solution 10 mg/ml in DMSO) was added to a final concentration of 5 
gg/mg lipid. 
2. 7. Protein estimation 
Protein was determined by the method of Bradford [16]. 
2.8. Dynamic fluorescence measurements and data analysis 
2.8.1. Frequency-domain measurements. Lifetime measurements 
were performed with a multifrequency phase fluorometer (ISS K2) 
interfaced with a PC 486 computer for data collection and analysis. 
The excitation wavelength was 280 nm (xenon arc lamp), emission 
being observed at 350+ 10 nm. Ten modulation frequencies between 
5 and 200 MHz were used. All measurements were obtained using 1,4- 
bis[2-5(phenyl)oxazolyl]benzene (POPOP, lifetime 1.35 ns; see [13]) in 
the reference cell. The temperature of the samples was maintained at 
25°C with an external bath circulator. Measurements and data ana- 
lysis were performed according to [20]. The optical density of the 
sample was maintained at Aa60=0.1. Corrections for background 
fluorescence and/or light scattering were made by performing the fre- 
quency-domain measurements with phospholipids without proteins as 
control sample and then correcting the data as in [17]. Notably, the 
addition of nystatin in DMSO resulted in an appearance of a much 
higher background signal in the control samples (liposomes without 
proteins PL and PE), which required the above correction. 
The experimental data were analyzed assuming either a sum of 
exponentials or a continuous distribution of lifetime values. A pro- 
gram provided by ISS (La Spezia, Italy) was used for the distribution 
analysis. For both exponential nd distribution analysis, this program 
minimizes the reduced chi-square, ZR 2 [18]. Za 2 was used to judge the 
goodness of fit of calculated functions with phase and modulation 
data. 
2.8.2. Time-domain measurements. The method of time-correlated 
single-photon counting was employed as reported elsewhere [19] with 
instrumentation a d data analysis as described previously [21]. The 
excitation wavelength was 280 nm and emission was observed at 
350-  +10 nm. 
2.9. Frrster energy transfer (FRET) calculations 
Calculated istances between donor and acceptor pairs can be de- 
rived from Frrster energy transfer measurements. The apparent effi- 
ciency E of energy transfer between a donor and an acceptor is de- 
pendent on the decrease in the donor lifetime after addition of an 
acceptor as folows: 
E = 1--(~DA/%) (I) 
where XDA and x A are the lifetimes of the donor in the presence and 
absence of the acceptor, respectively [13]. The efficiency E is related to 
the absolute rate of energy transfer kET as given below: 
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1 1 
k~,:T -- (2) 
"~DA %D 
where "~D and ZDA are the donor lifetimes in the absence and in the 
presence of the acceptor, respectively. If the donor has a continuous 
lifetime distribution rather than discrete lifetime(s), Xo and XDA should 
be replaced by mean values calculated over the distributions. 
For a two-component Lorentzian distribution, the mean reciprocal 
lifetime l/xa can be expressed as 
1 C¢1 "W1 Xl (~2 "W2 "~2 
~,~ : OCI"Wl + Ct'2"W2 ,£~ + W2 [" (XI'W1 -- (X2"W2 ,[;~ + W2 (3) 
where cq, (~2, ~1, x2, wl, w2 are the fractions, centres and full widths at 
half-maximum (FWHM) of the first and second component, respec- 
tively, cq+c~2=l, and the fractions refer to non-normalized Lorent- 
zians, i.e. they are peak heights rather than areas under the peak. 
Alternatively, we used the median as another, more standard mean 
value to calculate the FRET rates. The median XM is the value that 
divides the area under the distribution function into equal parts; for a 
two-component Lorentzian lifetime distribution, it can easily be found 
as the solution of the following equation: 
. f~,M--1;2 ~ 
0q'wl'arctg( " '~')wl + 0c2"w2"arc~g~)  = 0 (4) 
3. Results and discussion 
In order  to prove an altered relat ionship between mem- 
brane proteins and nystat in in the presence o f  ergosterol,  
the FRET  technique was used to est imate the distance be- 
tween t ryptophan residues in the proteins and nystat in in 
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Fig. 1. Extinction coefficient of nystatin (solid line) and fluorescence 
emission spectrum of tryptophan (dashed line) in 50 mM potassium 
phosphate buffer, pH 6.3. The excitation wavelength was 280 nm. 
The calculated critical distance R0=2.8 nm. 
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Table 1 
Two-component lifetime distribution analysis of tryptophan 
Sample zl W1 "~2 W2 fl[f2 "ITM "~R )~R 2 
(ns) (ns) (ns) (ns) (ns) (ns) 
PLM 3.6 4.1 0.10 0.05 49.0 3.5 4.2 4.2 
PEM 3.4 3.7 0.10 0.05 49.0 3.4 4.2 4.6 
PLM+N 3.9 0.3 0.10 0.05 4.0 3.7 1.0 4.5 
PEM+N 3.9 0.1 0.10 0.05 0.5 0.1 0.17 4.8 
Fluorescence lifetimes of PLM, PEM (266 gl) in 2 ml potassium 
phosphate buffer, pH 6.3, without nystatin (PLM, PEM) and with 
nystatin (5 Ixl, PLM+N, PEM+N); Xl, z2 represent the calculated 
lifetime components, Wl, w2 are the full-widths at half-maximum of
the Lorentzian lifetime distributions, andfflf2 is the ratio of fractional 
intensities oflifetime components ~ +f2 = 1). The average lifetimes xM 
and zrt are the median and the mean reciprocal lifetime, respectively. 
They were calculated as described in section 2. Reduced chi-square, 
Xrt 2, denotes the goodness of the fit of calculated functions with meas- 
ured data. 
yeast plasma membrane vesicles. The emission spectrum of 
tryptophan overlaps well with the absorption spectrum of 
nystatin (Fig. 1). Thus, tryptophan can serve as an energy 
donor and nystatin as an acceptor for F6rster energy transfer 
experiments. The calculated critical distance between trypto- 
phan and nystatin in a buffer was R0=2.8 nm. Hence, in this 
system it is possible to detect whether or not nystatin comes 
into close proximity (i.e. up to approx. 6 nm) of the protein, 
and how the presence of ergosterol affects this distance. To 
avoid the trivial errors often present in FRET calculations 
from steady-state spectra, dynamic measurements were per- 
formed and the efficiency of F6rster energy transfer was cal- 
culated from the lifetime of the tryptophan residue. 
First, the frequency-domain method was employed; the fre- 
quency response of the tryptophan fluorescence was recorded 
with modulations varying from 5 to 250 MHz and analyzed as 
described in Section 2. The goodness of fit was evaluated by 
the reduced chi-square, ;~a 2. The two-component Lorentzian 
distribution appeared as the best fit for the data, with ~R2=4.2 
(Table 1). Notably, while the Za 2 of the two-component 
Gaussian distribution was only slightly higher (5.3), the ZR 2 
of the two- or even three-exponential decays was significantly 
higher (24.3 and 19.5, respectively, data not shown). 
The short-lived component of the distribution had the cen- 
ter at x2 =0.1 ns and its fraction in the steady-state intensity 
was less than 2% while the long-lived component was centered 
at xl =3.6 ns for PLM (pure phospholipid vesicles) or xl =3.4 
ns for PEM (ergosterol containing vesicles). The calculated 
average lifetimes xa (mean reciprocal lifetime) were therefore 
3.6 and 3.4 ns for PLM and PEM, respectively. The full width 
at half-maximum (FWHM) of the long-lived components of 
the Lorentzian distribution was broad (w1=4.1 for PLM and 
w2=3.7 for PEM). This clearly indicated a heterogeneous pop- 
ulation of tryptophan residues reflecting a large variety of 
different membrane proteins in the plasma membrane vesicles. 
The heterogeneous microenvironment of individual trypto- 
phan residues in individual proteins probably contributes to 
the heterogeneous response. 
The ratio of the long-lived to the short-lived component 
0el/ J2) significantly decreased in the presence of nystatin (see 
Table 1). The fraction of the long-lived component in steady- 
state fluorescence intensity decreased from 98% in the absence 
of nystatin to 80% in its presence in PLM and to 34% in 
PEM. The average lifetime "~M (median) was 3.7 ns in PLM, 
decreasing significantly (to 0.1 ns) in PEM. 
Table 2 
Characteristic l fetimes of energy transfer 
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Sample ~a (ns) % (ns) 
PEM 1.3+0.10 0.4+0.1 
PLM 0.18 + 0.07 -0.03 + 0.1 
The characteristic l fetimes of energy transfer were obtained by the 
phase-domain method (x~, mean reciprocal lifetime from a two-com- 
ponent Lorentzian distribution) and the time-domain method ('~b, 
average lifetime from a double-exponential decay). 
An alternative method used to describe the F6rster energy 
transfer was based on the reciprocal value of the mean reci- 
procal ifetime Zrt (see Table 1). This value decreased from 4.2 
in the absence of nystatin to 1.0 and 0.17 in its presence in 
PLM and PEM, respectively. This clearly indicates the pres- 
ence of F6rster energy transfer in PEM with nystatin. While 
F6rster energy transfer in PLM with nystatin was not clearly 
demonstrated by the method using xM, the method making 
use of xa revealed a partial energy transfer also in this system. 
Nevertheless, with both methods the energy transfer in PEM 
was significantly higher than in PLM. 
Interestingly, the lifetime distribution was much more 
homogeneous in the presence of nystatin. This could indicate 
that one class (or a homogeneous population) of tryptophan 
residues could remain unaffected by nystatin. 
The experiments were repeated three times and the average 
characteristic lifetimes (i.e. the differences in average lifetimes 
zr~ in the systems without and with nystatin) of F6rster energy 
transfer were calculated for both systems (PEM and PLM). 
While the characteristic lifetime of FRET in PEM was 
1.3 + 0.3 ns, in PLM it decreased to 0.18 + 0.09 ns (see Table 
2). These experiments clearly indicated that the energy trans- 
fer was more pronounced in PEM than in PLM. In other 
words, nystatin was in a closer proximity to tryptophan resi- 
dues (and consequently to the protein) in ergosterol-contain- 
ing vesicles. 
To verify the above results and conclusions obtained with 
the frequency-domain pproach, an independent set of experi- 
ments with the same PEM and PLM samples was performed 
with a different instrumentation using a time-domain method 
yielding again a F6rster energy transfer estimation. As indi- 
cated in Table 2, a significantly higher rate of energy transfer 
was obtained in PEM (characteristic lifetime about 0.4 ns) 
relative to that in PLM (characteristic lifetime virtually 
zero). This again indicates a closer proximity of nystatin to 
proteins in ergosterol-containing vesicles. 
The above results, which document that nystatin is located 
in a much closer vicinity of membrane proteins in the presence 
of ergosterol than in its absence, indicate a possible interac- 
tion of this antibiotic with the proteins. Our data do not 
permit us to decide whether the effect reflects a direct nysta- 
tin-protein interaction or whether it represents merely an er- 
gosterol-mediated change in the relative orientation of nysta- 
tin and the proteins. In any case, its result is obviously a 
change in the functional state of the transport proteins, as 
seen in physiological studies which demonstrated that nystatin 
caused changes in the properties of transport systems recon- 
stituted in ergosterol-containing vesicles. Nystatin binding to 
ergosterol in the vicinity of an amino acid permease released 
this yeast transporter f om its coupling to energy and con- 
verted it to a facilitator [11]. A more defined system (e.g. a 
184 M. Opekarovd et al./FEBS Letters 386 (1996) 181-184 
single carrier protein reconstituted in the liposomes) is now 
required to provide further information. 
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